Keywords
Last Name
Institution

Scott Michael Lindhorst

Title
InstitutionMedical University of South Carolina
DepartmentNeurosurgery
AddressP.O. Box MSC 606
301
Clinical Science Bldg. - 96 Jonathan Lucas St.
Phone843-792-2568
Fax843-792-2234
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Scott Lindhorst, MD, joined the Division of Hematology/Oncology effective August 1, 2013 as an Assistant Professor. He also holds a dual appointment as an Assistant Professor in the Division of Neurosurgery.

    Dr. Lindhorst received his Bachelor of Science in Microbiology, with a minor in Chemistry, from the University of Florida in 2001 followed by his Medical Degree from the University of South Alabama College of Medicine in 2005. He completed a residency in Internal Medicine followed by a fellowship in Hematology and Medical Oncology at the University of Alabama at Birmingham School of Medicine. He also completed a fellowship in Neuro-Oncology at Duke University Medical Center in 2013. Dr. Lindhorst received clinical trials training at Massachusetts General Hospital, focusing on patients with amyotrophic lateral sclerosis.

    He is board-certified in General Internal Medicine, Hematology, and Medical Oncology by the American Board of Internal Medicine. He is also board-certified in Neuro-Oncology by the United Council for Neurologic Subspecialties.

    His practice will focus on patients with primary and metastatic malignancies of the central nervous system, as well as patients with head and neck cancers. Dr. Lindhorst looks forward to expanding his involvement in clinical trials and aiding in the growing need for new cancer treatments.

    Collapse keywords
    Cancer/Brain, Drug Studies, Men-s Health, Surgery, Vaccine, Cancer, Women-s Health, Brain Tumor, Glioblastoma

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Fox J, Ajinkya S, Houston P, Lindhorst S, Cachia D, Olar A, Kutluay E. Seizures in patents with primary central nervous system lymphoma: Prevalence and associated features. J Neurol Sci. 2019 May 15; 400:34-38. PMID: 30901566.
      View in: PubMed
    2. Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, Foulkes WD, Malkin D, Tabori U, Pearson CE. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. J Clin Oncol. 2019 Feb 20; 37(6):461-470. PMID: 30608896.
      View in: PubMed
    3. Das A, Henderson F, Lowe S, Wallace GC, Vandergrift WA, Lindhorst SM, Varma AK, Infinger LK, Giglio P, Banik NL, Patel SJ, Cachia D. Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma. Cancer Chemother Pharmacol. 2018 Dec; 82(6):945-952. PMID: 30209569.
      View in: PubMed
    4. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 06 29; 16(1):179. PMID: 29958537.
      View in: PubMed
    5. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 05 29; 16(1):142. PMID: 29843811.
      View in: PubMed
    6. Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A. Comprehensive Analysis of Hypermutation in Human Cancer. Cell. 2017 Nov 16; 171(5):1042-1056.e10. PMID: 29056344.
      View in: PubMed
    7. Roberts DR, Lindhorst SM, Welsh CT, Maravilla KR, Herring MN, Braun KA, Thiers BH, Davis WC. High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function. Invest Radiol. 2016 May; 51(5):280-9. PMID: 26953564.
      View in: PubMed
    8. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, Zhukova N, Mason G, Farah R, Afzal S, Yalon M, Rechavi G, Magimairajan V, Walsh MF, Constantini S, Dvir R, Elhasid R, Reddy A, Osborn M, Sullivan M, Hansford J, Dodgshun A, Klauber-Demore N, Peterson L, Patel S, Lindhorst S, Atkinson J, Cohen Z, Laframboise R, Dirks P, Taylor M, Malkin D, Albrecht S, Dudley RW, Jabado N, Hawkins CE, Shlien A, Tabori U. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol. 2016 07 01; 34(19):2206-11. PMID: 27001570.
      View in: PubMed
    9. Das A, McDonald DG, Dixon-Mah YN, Jacqmin DJ, Samant VN, Vandergrift WA, Lindhorst SM, Cachia D, Varma AK, Vanek KN, Banik NL, Jenrette JM, Raizer JJ, Giglio P, Patel SJ. RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma. Tumour Biol. 2016 Jun; 37(6):7525-34. PMID: 26684801.
      View in: PubMed
    10. Das A, Cheng RR, Hilbert ML, Dixon-Moh YN, Decandio M, Vandergrift WA, Banik NL, Lindhorst SM, Cachia D, Varma AK, Patel SJ, Giglio P. Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma. Cancer Growth Metastasis. 2015; 8:51-60. PMID: 26648752.
      View in: PubMed
    11. Das A, Miller R, Lee P, Holden CA, Lindhorst SM, Jaboin J, Vandergrift WA, Banik NL, Giglio P, Varma AK, Raizer JJ, Patel SJ. A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/ß-catenin signaling pathway. Tumour Biol. 2015 Sep; 36(9):7027-34. PMID: 25864108.
      View in: PubMed
    12. Lee P, Murphy B, Miller R, Menon V, Banik NL, Giglio P, Lindhorst SM, Varma AK, Vandergrift WA, Patel SJ, Das A. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res. 2015 Feb; 35(2):615-25. PMID: 25667438.
      View in: PubMed
    13. Agrawal NS, Miller R, Lal R, Mahanti H, Dixon-Mah YN, DeCandio ML, Vandergrift WA, Varma AK, Patel SJ, Banik NL, Lindhorst SM, Giglio P, Das A. Current Studies of Immunotherapy on Glioblastoma. J Neurol Neurosurg. 2014 Apr 05; 1(1). PMID: 25346943.
      View in: PubMed
    14. Lindhorst SM, Lopez RD, Sanders RD. An unusual presentation of chronic myelogenous leukemia: a review of isolated central nervous system relapse. J Natl Compr Canc Netw. 2013 Jul; 11(7):745-9; quiz 750. PMID: 23847213.
      View in: PubMed
    15. Lindhorst S, Cudkowicz M. Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis? Nat Clin Pract Neurol. 2006 Jul; 2(7):364-5. PMID: 16932586.
      View in: PubMed
    Lindhorst's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _